Loading
A phase 2 trial in pancreatic cancer, run by Institut Curie, now recruiting.
Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI) is a phase 2, interventional study registered as NCT06659705 by Institut Curie, with a registry enrolment figure of 35 participants, started 2025-12-02 and due to reach its primary completion in 2029-08-04. Interventions recorded: 68Ga-FAPI-46 for PET / CT scan. Conditions listed: Pancreatic Ductal Adenocarcinoma (PDAC). Primary outcome: EFS: Event Free Survival. Sites: France. No results are recorded here; the registry entry is the source.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.